Pliant Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Bernard Coulie

İcra Kurulu Başkanı

US$5.2m

Toplam tazminat

CEO maaş yüzdesi	10.7%
CEO görev süresi	7.2yrs
CEO sahipliği	0.9%
Yönetim ortalama görev süresi	7.1yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bernard Coulie'un ücretlendirmesi Pliant Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2022	n/a	n/a	-US$123m
Sep 30 2022	n/a	n/a	-US$113m
Jun 30 2022	n/a	n/a	-US$109m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$5m	US$556k	-US$97m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$2m	US$499k	-US$42m
Sep 30 2020	n/a	n/a	US$18m
Jun 30 2020	n/a	n/a	US$19m
Mar 31 2020	n/a	n/a	US$20m
Dec 31 2019	US$2m	US$428k	-US$7m

Tazminat ve Piyasa: Bernard 'nin toplam tazminatı ($USD 5.19M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.64M ).

Tazminat ve Kazançlar: Bernard şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Bernard Coulie (56 yo)

7.2yrs

Görev süresi

US$5,190,781

Tazminat

Dr. Bernard Coulie, Ph. D, M. D., M. B.A., serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairman since November 2022. He serves as President a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bernard Coulie	President	no data	US$5.19m	0.91% € 13.8m
Keith Cummings	Chief Financial Officer	4.3yrs	US$1.88m	0.16% € 2.4m
Mike Ouimette	General Counsel & Corporate Secretary	2.5yrs	US$805.04k	0.020% € 302.3k
Johannes Hull	Chief Business Officer	7.1yrs	US$1.65m	0.30% € 4.6m
Éric Lefebvre	Chief Medical Officer	4.9yrs	US$1.97m	Veri yok
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	Veri yok	Veri yok
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	Veri yok	Veri yok
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	Veri yok	Veri yok
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	Veri yok	Veri yok
Craig Muir	Interim Chief Technology Officer	no data	Veri yok	Veri yok
Christopher Keenan	Vice President of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Lily Cheung	Chief Human Resources Officer	less than a year	Veri yok	Veri yok

7.1yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 9PT 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bernard Coulie	President	7.2yrs	US$5.19m	0.91% € 13.8m
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gayle Crowell	Independent Director	3.3yrs	US$287.91k	0% € 0
Brian Metcalf	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Suzanne Bruhn	Independent Director	6.8yrs	US$288.29k	0.059% € 899.3k
John Curnutte	Independent Director	5.7yrs	US$286.41k	0.049% € 750.6k
Hoyoung Huh	Independent Chairman	5.3yrs	US$308.41k	0% € 0
Smital Shah	Independent Director	4.1yrs	US$288.41k	0% € 0
Bill Greenlee	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 9PT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Pliant Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Recent updates

Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs

Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

Insufficient new directors

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings released: US$0.65 loss per share (vs US$0.75 loss in 3Q 2021)

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.64 loss in 2Q 2021)

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.64 loss in 1Q 2021)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expected 2022 Milestones

Third quarter 2021 earnings released: US$0.75 loss per share (vs US$0.47 loss in 3Q 2020)

Pliant Therapeutics, Inc. Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.64 loss per share

Pliant Therapeutics, Inc. Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €28.60

Investor sentiment improved over the past week

New 90-day high: €26.40

Pliant Therapeutics, Inc. Announces Appointment of David Pyott to Board of Directors

Investor sentiment improved over the past week

New 90-day high: €24.21

Pliant Therapeutics Appoints Mike Ouimette as General Counsel and Corporate Secretary

New 90-day low: €19.00

Pliant Therapeutics, Inc. announced that it expects to receive $45 million in funding

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş